Data / Drug companies / Rivastigmine
Rivastigmine: 11 companies and 34 products in the FDA NDC directory
Rivastigmine is listed in the FDA National Drug Code Directory by 11 companies, with 34 products in commercial distribution. 25 of the products (73.5%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are patch, extended release; patch, and the newest product started marketing on December 19, 2019.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 11
- Products
- 34
- Generic (ANDA) products
- 25 (73.5%)
- Application numbers
- 5
- Routes
- Transdermal
- Brand names
- Exelon
- openFDA record search
- api.fda.gov
Companies that list rivastigmine
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Bryant Ranch Prepack | 5 | patch, extended release | Generic drugs (ANDA) | December 19, 2019 |
| Amneal Pharmaceuticals LLC | 3 | patch | Generic drugs (ANDA) | June 30, 2015 |
| Breckenridge Pharmaceutical, Inc. | 3 | patch, extended release | Generic drugs (ANDA) | December 19, 2019 |
| Bryant Ranch Prepack | 3 | patch, extended release | Generic drugs (ANDA) | December 19, 2019 |
| Mylan Pharmaceuticals Inc. | 3 | patch | Generic drugs (ANDA) | June 20, 2018 |
| Novartis Pharmaceuticals Corporation | 3 | patch, extended release | New drug applications (NDA) | July 6, 2007 |
| Sandoz Inc | 3 | patch, extended release | Authorized generics (NDA) | September 2, 2015 |
| Sandoz Inc | 3 | patch, extended release | New drug applications (NDA) | July 6, 2007 |
| Zydus Lifesciences Limited | 3 | patch, extended release | Generic drugs (ANDA) | March 6, 2019 |
| Zydus Pharmaceuticals USA Inc. | 3 | patch, extended release | Generic drugs (ANDA) | March 6, 2019 |
| NorthStar Rx LLC | 2 | patch, extended release | Generic drugs (ANDA) | October 1, 2019 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Patch, extended release | 28 | 82.4% |
| Patch | 6 | 17.6% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 25 | 73.5% |
| New drug applications (NDA) | 6 | 17.6% |
| Authorized generics (NDA) | 3 | 8.8% |
Pharmacologic classes
| Class | Products |
|---|---|
| Cholinesterase Inhibitor | 34 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.